Windtree announces positive Phase 2b topline results for istaroxime in early cardiogenic shock

WINDTREE THERAPEUTICS INC /DE/

Istaroxime met primary endpoint: significantly improved systolic blood pressure profile over six hours vs placebo.
Significant improvements in many secondary endpoints; safety profile favorable, consistent with prior trials.
Study tested two dosing regimens (decreasing and constant) over up to 60 hours infusion to optimize late-stage design.
Detailed results to be presented at Heart Failure Society of America on Sept 30, 2024; investor call planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.